Android app Apple app link

Nuvectis Pharma CEO Says Increased Dose Intensity Needed To Drive More Efficacy From Ovarian Cancer Lead Drug

By Yahoo! Finance   |   1 year ago
Nuvectis Pharma CEO Says Increased Dose Intensity Needed To Drive More Efficacy From Ovarian Cancer Lead Drug

Nuvectis Pharma, Inc. stock declined due to Phase 1b study results on NXP800 for ovarian cancer. Efficacy was observed with some patients showing tumor responses. The company plans to increase dosage intensity for better results.

Read More

Did you find this insightful?

Exclusive Content

Access to this content is reserved for premium members. Unlock all features by upgrading to a premium membership.

Get the App

To join as a premium member, please download our app and complete your membership purchase there.